Project Details
Description
A Randomized, Double-blind, Placebo-controlled, Phase 2 Clinical Trial of Allisertib (MLN8237) in Combination With Paclitaxel Versus Placebo in Combination With Paclitaxel as Second Line Therapy for Small Cell Lung Cancer (SCLC)
| Status | Finished |
|---|---|
| Effective start/end date | 3/17/14 → 3/29/20 |
Funding
- MILLENNIUM PHARMACEUTICALS, INC.
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.